Finch Therapeutics FNCH Stock
Finch Therapeutics Price Chart
Finch Therapeutics FNCH Financial and Trading Overview
| Finch Therapeutics stock price | 9.2 USD |
| Previous Close | 9.2 USD |
| Open | 11.9 USD |
| Bid | 7.7 USD x 70000 |
| Ask | 7.9 USD x 10000 |
| Day's Range | 5.01 - 11.91 USD |
| 52 Week Range | 2 - 16.1 USD |
| Volume | 71.79K USD |
| Avg. Volume | 3.65K USD |
| Market Cap | 14.77M USD |
| Beta (5Y Monthly) | 1.174 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
FNCH Valuation Measures
| Enterprise Value | 25.78M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.44681883 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 1.038961 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.322 |
Trading Information
Finch Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.174 |
| 52-Week Change | -35.43% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 16.1 USD |
| 52 Week Low | 2 USD |
| 50-Day Moving Average | 12.77 USD |
| 200-Day Moving Average | 12.96 USD |
FNCH Share Statistics
| Avg. Volume (3 month) | 3.65K USD |
| Avg. Daily Volume (10-Days) | 16.38K USD |
| Shares Outstanding | 1.61M |
| Float | 1.56M |
| Short Ratio | 0.19 |
| % Held by Insiders | 3.40% |
| % Held by Institutions | 0% |
| Shares Short | 19.2K |
| Short % of Float | 2.75% |
| Short % of Shares Outstanding | 1.19% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -21.89% |
| Return on Equity (ttm) | -67.28% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 0 USD |
| EBITDA | -19506000 USD |
| Net Income Avi to Common (ttm) | -14167000 USD |
| Diluted EPS (ttm) | -8.8 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.04M USD |
| Total Cash Per Share (mrq) | 9.99 USD |
| Total Debt (mrq) | 28.99M USD |
| Total Debt/Equity (mrq) | 203.88 USD |
| Current Ratio (mrq) | 3.872 |
| Book Value Per Share (mrq) | 8.855 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18055000 USD |
| Levered Free Cash Flow (ttm) | -15963625 USD |
Profile of Finch Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 75 State Street |
| ZIP | 02109 |
| Phone | 617 229 6499 |
| Website | https://www.finchtherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Q&A For Finch Therapeutics Stock
What is a current FNCH stock price?
Finch Therapeutics FNCH stock price today per share is 9.2 USD.
How to purchase Finch Therapeutics stock?
You can buy FNCH shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Finch Therapeutics?
The stock symbol or ticker of Finch Therapeutics is FNCH.
Which industry does the Finch Therapeutics company belong to?
The Finch Therapeutics industry is Biotechnology.
How many shares does Finch Therapeutics have in circulation?
The max supply of Finch Therapeutics shares is 1.61M.
What is Finch Therapeutics Price to Earnings Ratio (PE Ratio)?
Finch Therapeutics PE Ratio is 0.00000000 now.
What was Finch Therapeutics earnings per share over the trailing 12 months (TTM)?
Finch Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Finch Therapeutics company belong to?
The Finch Therapeutics sector is Healthcare.
Finch Therapeutics FNCH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}